RNA Avidity Biosciences, Inc.

Nasdaq aviditybiosciences.com


$ 51.48 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 06:07:58 EDT
QQQ $ 605.63 $ 0.00 (0 %)
DIA $ 463.75 $ 0.00 (0 %)
SPY $ 667.66 $ 0.00 (0 %)
TLT $ 90.92 $ 0.00 (0 %)
GLD $ 390.22 $ 0.00 (0 %)
$ 50.47
$ 48.21
$ 50.47 x 1
$ 51.50 x 1,070
-- - --
$ 21.51 - $ 56.00
1,781,581
na
6.49B
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 avidity-biosciences-to-present-phase-12-data-on-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy-at-2025-world-muscle-society-congress

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics cal...

 evercore-isi-group-maintains-outperform-on-avidity-biosciences-lowers-price-target-to-65

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price t...

 roth-capital-initiates-coverage-on-avidity-biosciences-with-buy-rating-announces-price-target-of-62

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Buy rating and anno...

 b-of-a-securities-maintains-buy-on-avidity-biosciences-raises-price-target-to-65

B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target fr...

 avidity-biosciences-files-for-offering-of-15m-shares-of-common-stock

-SEC Filing

 hc-wainwright--co-maintains-buy-on-avidity-biosciences-raises-price-target-to-87

HC Wainwright & Co. analyst Ananda Ghosh maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price targ...

 avidity-drug-shows-yearlong-gains-in-duchenne-muscular-dystrophy-trial

Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne ...

 needham-maintains-buy-on-avidity-biosciences-raises-price-target-to-65

Needham analyst Joseph Stringer maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $60 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION